Oncotelic Therapeutics(OTLC)
$0.010.00 (0.00%)
OTLC
Oncotelic Therapeutics financials statements
$0.01
At close:0.00 (0.00%)
Want to see OTLC full AI Analyst Report?
Oncotelic Therapeutics (OTLC) Ratios
86 Followers
Oncotelic Therapeutics Ratios
OTLC's free cash flow for Q2 2026 was $-92.20K. For the 2026 fiscal year, OTLC's free cash flow was increased by $0.00 and operating cash flow was $-92.20K. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Dec 23 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.07 | 0.01 | 0.02 | 0.02 | 0.04 |
| Quick Ratio | 0.07 | 0.01 | 0.02 | 0.02 | 0.04 |
| Cash Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.04 |
| Solvency Ratio | 1.90 | -235.60 | -0.43 | 1.05 | -0.73 |
| Operating Cash Flow Ratio | -0.08 | -0.04 | -0.08 | -0.09 | -0.29 |
| Short-Term Operating Cash Flow Coverage | -0.11 | -0.06 | -0.12 | -0.13 | -0.49 |
| Net Current Asset Value | $ -130.16M | $ -19.07M | $ -18.13M | $ -16.62M | $ -14.83M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.49 | 0.42 | 0.31 | 0.38 |
| Debt-to-Equity Ratio | 0.05 | 1.59 | 1.04 | 0.58 | 1.13 |
| Debt-to-Capital Ratio | 0.05 | 0.61 | 0.51 | 0.37 | 0.53 |
| Long-Term Debt-to-Capital Ratio | 0.01 | 0.00 | 0.14 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.50 | 3.23 | 2.47 | 1.86 | 2.97 |
| Debt Service Coverage Ratio | 19.03 | -0.25 | -0.61 | -0.39 | -0.82 |
| Interest Coverage Ratio | -3.60 | -4169.19 | -6.36 | -3.27 | -4.56 |
| Debt to Market Cap | 0.42 | 0.92 | 0.83 | 0.65 | 0.17 |
| Interest Debt Per Share | 0.04 | 0.03 | 0.03 | 0.04 | 0.04 |
| Net Debt to EBITDA | 0.04 | -3.67 | -1.73 | -1.97 | -0.93 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | -10230.40% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | -10230.39% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | -9497.16% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | -11722.95% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | -11290.13% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -11722.95% | 0.00% | 0.00% |
| Net Income Per EBT | 69.13% | 100.00% | 96.31% | 381.04% | 108.33% |
| EBT Per EBIT | -11315.35% | 126.51% | 123.44% | -48.11% | 115.25% |
| Return on Assets (ROA) | 63.42% | -16957.90% | -26.33% | 49.34% | -48.25% |
| Return on Equity (ROE) | 94.87% | -54824.70% | -65.15% | 91.81% | -143.22% |
| Return on Capital Employed (ROCE) | -0.85% | -47823.57% | -49.21% | -50.65% | -111.86% |
| Return on Invested Capital (ROIC) | -0.57% | -17388.34% | -27.49% | -31.93% | -53.21% |
| Return on Tangible Assets | 64.05% | -19852.75% | -34.47% | 77.67% | -1816.35% |
| Earnings Yield | 755.17% | -31962.49% | -52.15% | 103.10% | -22.11% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 3.69 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 3.08 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 98.95 | -49338.36 | -11320.02 |
| Days of Sales Outstanding | 0.00 | 0.00 | 98.95 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 118.67 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 49338.36 | 11438.69 |
| Operating Cycle | 0.00 | 0.00 | 98.95 | 0.00 | 118.67 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -246755.67 | -440349.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -246755.67 | -440349.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.10 | -0.06 | -0.11 | -0.13 | -0.49 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -18.87 | 0.00 | 0.00 |
| Free Cash Flow Yield | -4.19% | -5.23% | -8.72% | -8.40% | -8.61% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 0.13 | -3.13 | -1.92 | 0.97 | -4.52 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 216.48 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.13 | 1.72 | 1.25 | 0.89 | 6.48 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -23.87 | -19.12 | -11.47 | -11.90 | -11.62 |
| Price-to-Operating Cash Flow Ratio | -23.87 | -19.12 | -11.47 | -11.90 | -11.62 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.07 | 0.01 | -0.00 | 0.06 |
| Enterprise Value Multiple | 0.13 | -7.66 | -3.85 | -5.06 | -6.61 |
| Enterprise Value | 46.83M | 27.16M | 27.56M | 28.30M | 59.95M |
| EV to EBITDA | 0.13 | -7.66 | -3.85 | -5.06 | -6.61 |
| EV to Sales | 0.00 | 0.00 | 393.67 | 0.00 | 0.00 |
| EV to Free Cash Flow | -33.86 | -36.68 | -20.86 | -19.48 | -13.52 |
| EV to Operating Cash Flow | -33.86 | -36.68 | -20.86 | -19.48 | -13.52 |
| Tangible Book Value Per Share | 0.61 | 0.01 | 0.01 | 0.02 | -0.05 |
| Shareholders’ Equity Per Share | 0.62 | 0.02 | 0.03 | 0.05 | 0.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | 0.59 | -11.19 | -0.02 | 0.05 | -0.04 |
| Tax Burden | 0.69 | 1.00 | 0.96 | 3.81 | 1.08 |
| Interest Burden | 1.00 | 1153.55 | 1.15 | -0.83 | 1.15 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.87 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 8.20 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.01 | 1.13 | 0.17 | -0.31 | 0.42 |
Currency in USD

